Research ArticleArticle
Open Access
Effectiveness of 6-month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Philip J. Mease, Taylor Blachley, Blessing Dube, Robert R. McLean, Nina Kim, Peter Hur and Alexis Ogdie
The Journal of Rheumatology April 2022, jrheum.211033; DOI: https://doi.org/10.3899/jrheum.211033
Philip J. Mease
This study was sponsored by CorEvitas, LLC ( formerly Corrona). CorEvitas, LLC, has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, BMS, Celgene, Crescendo, Eli Lilly, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Roche, Sun, and UCB. The design and conduct of the study were a collaborative effort between CorEvitas, LLC, and Novartis, and financial support for the study was provided by Novartis. Novartis participated in the interpretation of data and review and approval of the manuscript. P.J. Mease, MD, MACR, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, Washington; T. Blachley, MS, B. Dube, MPH, R.R. McLean, DSc, MPH, CorEvitas, LLC, Waltham, Massachusetts; N. Kim, PharmD, The University of Texas at Austin and Baylor Scott and White Health, Temple, Texas; P. Hur, PharmD, MBA, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; A. Ogdie, MD, MCSE, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. PJM has received research grants from AbbVie, Amgen, BMS, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, Sun Pharma, and UCB; consulting fees from AbbVie, Amgen, Boehringer Ingelheim, BMS, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Novartis, Pfizer, Sun Pharma, and UCB; and speakers bureau fees from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. TB, BD, and RRM are employees of CorEvitas, LLC. NK was a postdoctoral fellow at the University of Texas at Austin and Baylor Scott and White Health at the time of this analysis, providing services to Novartis, and is currently an employee of Novo Nordisk. PH was an employee of Novartis at the time of this study and is currently an employee of Pfizer. AO has received consulting fees from Amgen, AbbVie, BMS, Celgene, Gilead, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, and has received grant support from the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, Rheumatology Research Foundation, National Psoriasis Foundation, Amgen, Pfizer, and Novartis. Address correspondence to Dr. P.J. Mease, Swedish Medical Center/Providence St. Joseph Health and University of Washington; 601 Broadway, Suite 600, Seattle, WA 98122, USA. Email: pmease@philipmease.com. Accepted for publication March 29, 2022.
Taylor Blachley
This study was sponsored by CorEvitas, LLC ( formerly Corrona). CorEvitas, LLC, has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, BMS, Celgene, Crescendo, Eli Lilly, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Roche, Sun, and UCB. The design and conduct of the study were a collaborative effort between CorEvitas, LLC, and Novartis, and financial support for the study was provided by Novartis. Novartis participated in the interpretation of data and review and approval of the manuscript. P.J. Mease, MD, MACR, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, Washington; T. Blachley, MS, B. Dube, MPH, R.R. McLean, DSc, MPH, CorEvitas, LLC, Waltham, Massachusetts; N. Kim, PharmD, The University of Texas at Austin and Baylor Scott and White Health, Temple, Texas; P. Hur, PharmD, MBA, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; A. Ogdie, MD, MCSE, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. PJM has received research grants from AbbVie, Amgen, BMS, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, Sun Pharma, and UCB; consulting fees from AbbVie, Amgen, Boehringer Ingelheim, BMS, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Novartis, Pfizer, Sun Pharma, and UCB; and speakers bureau fees from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. TB, BD, and RRM are employees of CorEvitas, LLC. NK was a postdoctoral fellow at the University of Texas at Austin and Baylor Scott and White Health at the time of this analysis, providing services to Novartis, and is currently an employee of Novo Nordisk. PH was an employee of Novartis at the time of this study and is currently an employee of Pfizer. AO has received consulting fees from Amgen, AbbVie, BMS, Celgene, Gilead, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, and has received grant support from the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, Rheumatology Research Foundation, National Psoriasis Foundation, Amgen, Pfizer, and Novartis. Address correspondence to Dr. P.J. Mease, Swedish Medical Center/Providence St. Joseph Health and University of Washington; 601 Broadway, Suite 600, Seattle, WA 98122, USA. Email: pmease@philipmease.com. Accepted for publication March 29, 2022.
Blessing Dube
This study was sponsored by CorEvitas, LLC ( formerly Corrona). CorEvitas, LLC, has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, BMS, Celgene, Crescendo, Eli Lilly, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Roche, Sun, and UCB. The design and conduct of the study were a collaborative effort between CorEvitas, LLC, and Novartis, and financial support for the study was provided by Novartis. Novartis participated in the interpretation of data and review and approval of the manuscript. P.J. Mease, MD, MACR, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, Washington; T. Blachley, MS, B. Dube, MPH, R.R. McLean, DSc, MPH, CorEvitas, LLC, Waltham, Massachusetts; N. Kim, PharmD, The University of Texas at Austin and Baylor Scott and White Health, Temple, Texas; P. Hur, PharmD, MBA, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; A. Ogdie, MD, MCSE, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. PJM has received research grants from AbbVie, Amgen, BMS, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, Sun Pharma, and UCB; consulting fees from AbbVie, Amgen, Boehringer Ingelheim, BMS, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Novartis, Pfizer, Sun Pharma, and UCB; and speakers bureau fees from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. TB, BD, and RRM are employees of CorEvitas, LLC. NK was a postdoctoral fellow at the University of Texas at Austin and Baylor Scott and White Health at the time of this analysis, providing services to Novartis, and is currently an employee of Novo Nordisk. PH was an employee of Novartis at the time of this study and is currently an employee of Pfizer. AO has received consulting fees from Amgen, AbbVie, BMS, Celgene, Gilead, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, and has received grant support from the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, Rheumatology Research Foundation, National Psoriasis Foundation, Amgen, Pfizer, and Novartis. Address correspondence to Dr. P.J. Mease, Swedish Medical Center/Providence St. Joseph Health and University of Washington; 601 Broadway, Suite 600, Seattle, WA 98122, USA. Email: pmease@philipmease.com. Accepted for publication March 29, 2022.
Robert R. McLean
This study was sponsored by CorEvitas, LLC ( formerly Corrona). CorEvitas, LLC, has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, BMS, Celgene, Crescendo, Eli Lilly, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Roche, Sun, and UCB. The design and conduct of the study were a collaborative effort between CorEvitas, LLC, and Novartis, and financial support for the study was provided by Novartis. Novartis participated in the interpretation of data and review and approval of the manuscript. P.J. Mease, MD, MACR, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, Washington; T. Blachley, MS, B. Dube, MPH, R.R. McLean, DSc, MPH, CorEvitas, LLC, Waltham, Massachusetts; N. Kim, PharmD, The University of Texas at Austin and Baylor Scott and White Health, Temple, Texas; P. Hur, PharmD, MBA, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; A. Ogdie, MD, MCSE, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. PJM has received research grants from AbbVie, Amgen, BMS, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, Sun Pharma, and UCB; consulting fees from AbbVie, Amgen, Boehringer Ingelheim, BMS, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Novartis, Pfizer, Sun Pharma, and UCB; and speakers bureau fees from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. TB, BD, and RRM are employees of CorEvitas, LLC. NK was a postdoctoral fellow at the University of Texas at Austin and Baylor Scott and White Health at the time of this analysis, providing services to Novartis, and is currently an employee of Novo Nordisk. PH was an employee of Novartis at the time of this study and is currently an employee of Pfizer. AO has received consulting fees from Amgen, AbbVie, BMS, Celgene, Gilead, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, and has received grant support from the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, Rheumatology Research Foundation, National Psoriasis Foundation, Amgen, Pfizer, and Novartis. Address correspondence to Dr. P.J. Mease, Swedish Medical Center/Providence St. Joseph Health and University of Washington; 601 Broadway, Suite 600, Seattle, WA 98122, USA. Email: pmease@philipmease.com. Accepted for publication March 29, 2022.
Nina Kim
This study was sponsored by CorEvitas, LLC ( formerly Corrona). CorEvitas, LLC, has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, BMS, Celgene, Crescendo, Eli Lilly, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Roche, Sun, and UCB. The design and conduct of the study were a collaborative effort between CorEvitas, LLC, and Novartis, and financial support for the study was provided by Novartis. Novartis participated in the interpretation of data and review and approval of the manuscript. P.J. Mease, MD, MACR, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, Washington; T. Blachley, MS, B. Dube, MPH, R.R. McLean, DSc, MPH, CorEvitas, LLC, Waltham, Massachusetts; N. Kim, PharmD, The University of Texas at Austin and Baylor Scott and White Health, Temple, Texas; P. Hur, PharmD, MBA, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; A. Ogdie, MD, MCSE, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. PJM has received research grants from AbbVie, Amgen, BMS, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, Sun Pharma, and UCB; consulting fees from AbbVie, Amgen, Boehringer Ingelheim, BMS, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Novartis, Pfizer, Sun Pharma, and UCB; and speakers bureau fees from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. TB, BD, and RRM are employees of CorEvitas, LLC. NK was a postdoctoral fellow at the University of Texas at Austin and Baylor Scott and White Health at the time of this analysis, providing services to Novartis, and is currently an employee of Novo Nordisk. PH was an employee of Novartis at the time of this study and is currently an employee of Pfizer. AO has received consulting fees from Amgen, AbbVie, BMS, Celgene, Gilead, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, and has received grant support from the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, Rheumatology Research Foundation, National Psoriasis Foundation, Amgen, Pfizer, and Novartis. Address correspondence to Dr. P.J. Mease, Swedish Medical Center/Providence St. Joseph Health and University of Washington; 601 Broadway, Suite 600, Seattle, WA 98122, USA. Email: pmease@philipmease.com. Accepted for publication March 29, 2022.
Peter Hur
This study was sponsored by CorEvitas, LLC ( formerly Corrona). CorEvitas, LLC, has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, BMS, Celgene, Crescendo, Eli Lilly, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Roche, Sun, and UCB. The design and conduct of the study were a collaborative effort between CorEvitas, LLC, and Novartis, and financial support for the study was provided by Novartis. Novartis participated in the interpretation of data and review and approval of the manuscript. P.J. Mease, MD, MACR, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, Washington; T. Blachley, MS, B. Dube, MPH, R.R. McLean, DSc, MPH, CorEvitas, LLC, Waltham, Massachusetts; N. Kim, PharmD, The University of Texas at Austin and Baylor Scott and White Health, Temple, Texas; P. Hur, PharmD, MBA, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; A. Ogdie, MD, MCSE, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. PJM has received research grants from AbbVie, Amgen, BMS, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, Sun Pharma, and UCB; consulting fees from AbbVie, Amgen, Boehringer Ingelheim, BMS, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Novartis, Pfizer, Sun Pharma, and UCB; and speakers bureau fees from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. TB, BD, and RRM are employees of CorEvitas, LLC. NK was a postdoctoral fellow at the University of Texas at Austin and Baylor Scott and White Health at the time of this analysis, providing services to Novartis, and is currently an employee of Novo Nordisk. PH was an employee of Novartis at the time of this study and is currently an employee of Pfizer. AO has received consulting fees from Amgen, AbbVie, BMS, Celgene, Gilead, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, and has received grant support from the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, Rheumatology Research Foundation, National Psoriasis Foundation, Amgen, Pfizer, and Novartis. Address correspondence to Dr. P.J. Mease, Swedish Medical Center/Providence St. Joseph Health and University of Washington; 601 Broadway, Suite 600, Seattle, WA 98122, USA. Email: pmease@philipmease.com. Accepted for publication March 29, 2022.
Alexis Ogdie
This study was sponsored by CorEvitas, LLC ( formerly Corrona). CorEvitas, LLC, has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, BMS, Celgene, Crescendo, Eli Lilly, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Roche, Sun, and UCB. The design and conduct of the study were a collaborative effort between CorEvitas, LLC, and Novartis, and financial support for the study was provided by Novartis. Novartis participated in the interpretation of data and review and approval of the manuscript. P.J. Mease, MD, MACR, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, Washington; T. Blachley, MS, B. Dube, MPH, R.R. McLean, DSc, MPH, CorEvitas, LLC, Waltham, Massachusetts; N. Kim, PharmD, The University of Texas at Austin and Baylor Scott and White Health, Temple, Texas; P. Hur, PharmD, MBA, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; A. Ogdie, MD, MCSE, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. PJM has received research grants from AbbVie, Amgen, BMS, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, Sun Pharma, and UCB; consulting fees from AbbVie, Amgen, Boehringer Ingelheim, BMS, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Novartis, Pfizer, Sun Pharma, and UCB; and speakers bureau fees from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. TB, BD, and RRM are employees of CorEvitas, LLC. NK was a postdoctoral fellow at the University of Texas at Austin and Baylor Scott and White Health at the time of this analysis, providing services to Novartis, and is currently an employee of Novo Nordisk. PH was an employee of Novartis at the time of this study and is currently an employee of Pfizer. AO has received consulting fees from Amgen, AbbVie, BMS, Celgene, Gilead, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, and has received grant support from the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, Rheumatology Research Foundation, National Psoriasis Foundation, Amgen, Pfizer, and Novartis. Address correspondence to Dr. P.J. Mease, Swedish Medical Center/Providence St. Joseph Health and University of Washington; 601 Broadway, Suite 600, Seattle, WA 98122, USA. Email: pmease@philipmease.com. Accepted for publication March 29, 2022.
Article Figures & Data
Additional Files
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Effectiveness of 6-month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Philip J. Mease, Taylor Blachley, Blessing Dube, Robert R. McLean, Nina Kim, Peter Hur, Alexis Ogdie
The Journal of Rheumatology Apr 2022, jrheum.211033; DOI: 10.3899/jrheum.211033
Effectiveness of 6-month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Philip J. Mease, Taylor Blachley, Blessing Dube, Robert R. McLean, Nina Kim, Peter Hur, Alexis Ogdie
The Journal of Rheumatology Apr 2022, jrheum.211033; DOI: 10.3899/jrheum.211033